Nuformix PLC Reports Results from Novel IPF Pre-Clinical Trial (1394J)
December 03 2018 - 2:00AM
UK Regulatory
TIDMNFX
RNS Number : 1394J
Nuformix PLC
03 December 2018
Nuformix plc
("Nuformix" or the "Company")
Nuformix Reports Results from Novel Pre-Clinical Trial in IPF
for NXP002 Programme
Data show Nuformix Investigational Candidates (NXP002)
outperform current standard of care
Cambridge, UK, 3rd December 2018: Nuformix, the pharmaceutical
development company using cocrystal technology to unlock the
therapeutic potential of approved small molecule drugs, announces
results from the completion of its innovative pre-clinical trial
for its NXP002 fibrosis programme in human idiopathic pulmonary
fibrosis ('IPF') against standard of care[1].
Multi-patient tissue studies were performed in partnership with
Newcastle University, UK using a leading-edge human tissue trial
model that closely replicates the clinical disease:
-- Data demonstrates NXP002 candidates strongly inhibit fibrosis
ex-vivo, even in very severely fibrotic patient tissue, giving
strong support for treating IPF and other fibrotic lung
conditions
-- In addition, NXP002 demonstrated specific action measured against key inflammatory targets
-- NXP002 out-performed current standard of care treatment, Esbriet (R) (pirfenidone)
In partnership with the Newcastle University Fibrosis Research
Group, UK, these results are the first of their kind to be
published. Despite this being a challenging model of end-stage
disease, the outcomes are considered highly positive and a portent
for wider applications in other fibrotic lung conditions.
Dr Dan Gooding, CEO, Nuformix plc, said: "Despite the advent of
new treatments, life expectancy has not really changed for patients
diagnosed with IPF. Few patients respond to current treatments and
have to tolerate severe side effects that dramatically impact
quality of life - severe vomiting on one therapy or severe
diarrhoea on the other. This promising data gives us confidence in
our ability to both inhibit fibrosis and attenuate inflammation in
patients without these side effects.
"Newcastle University use a highly innovative new human tissue
model, which has the potential to become the new gold standard for
pre-clinical studies. These findings are important for IPF patients
and show our NXP002 programme can play an important role in
improving on current treatment options and extending both life and
its quality."
Nuformix will now seek to optimise delivery of a candidate
within its NXP002 programme to maximise efficacy and tolerability
using its patented novel drug forms before moving into patient
studies.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 423667
Optimum Strategic Communications
Supriya Mathur, Mary Clark +44 (0) 203 950
Email: nuformix@optimumcomms.com 9144
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
About Fibrosis
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Whilst, fibrosis treatments are in their infancy the
emerging lung fibrosis market demonstrates their blockbuster
potential. Markets for other fibrotic conditions are
under-developed, with large and growing patient populations (e.g.
the global liver disease market is predicted to reach $12.1 billion
by 2022). IPF is classified as a rare disease, and presents a
global commercial market that is forecast to grow to $5bn by
2025.
Nuformix filed an additional patent in September 2018 relating
to NXP002 products in order to capture a wider range of options in
the treatment of fibrosis given its broad anti-fibrotic potential
with relevance to unmet needs in multiple life-threatening
conditions.
About the IPF Model
Ground-breaking research at Newcastle University, UK has
validated the use of post-transplant human fibrotic lung tissue to
evaluate new therapies. The model uniquely represents an
'in-patient' scenario unlike any current pre-clinical model, where
fibrotic tissue is kept alive and functional allowing the impact of
prevention of disease progression to be accurately assessed. The
data are generated from patients with end-stage IPF, presenting
high fibrosis in the lung tissue where the only chance of survival
was a lung transplant. The resulting data are the first to be
reported in multiple patient IPF lung tissues, yet offers patients
the possibility of reduced side-effects, which are currently so
severe that roughly 40% of patients cease treatment.
[1] (Pirfenidone, Esbriet (R)), Esbriet (Pirfenidone, Roche) and
OFEV (Nintedanib, BI) are the only approved treatments.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUARARWUAURAA
(END) Dow Jones Newswires
December 03, 2018 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2023 to Apr 2024
